Targeting inflammation to slow or delay functional decline: where are we?
Authors: Corsonello A, Garasto S, Abbatecola AM, Rose G, Passarino G, Mazzei B, Pranno L, Guffanti EE, Bustacchini S, Lattanzio F
Date: 2010
Scope of interest: biogerontology
06 99 39
Recup number
You may also be interested in:
Myoclonic epilepsy, parkinsonism, schizophrenia and left-handedness as common neuropsychiatric features in 22q11.2 deletion syndrome.
Authors: Fanella M, Frascarelli M, Lambiase C, Morano A, Unolt M, Liberati N, Fattouch J, Buzzanca A, Accinni T, Ceccanti M, Viganò A, Biondi M, Colonnese C, Giallonardo AT, Di Fabio F, Pizzuti A, Di Bonaventura C, Berardelli A.
Date: 2019
Scope of interest: Epilepsy/movement disorders/psychiatric disorders
Read details
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine kinase inhibitors
Authors: Benedetta Stefanini et al
Date: 22 Nov 2023
Scope of interest: hepatological
Read details
Poor Mobilizer” with myeloma or lymphoma. Experience of the”Tor Vergata”Polyclinic Stem Cell Collection Center
Authors: Fiorelli E., Lanti A., Ferraro A.S., D’Alessandro E., Chiru O.M., Del Proposto G., Cerrone P., De Angelis L., Guiducci G., Zinno F., Adorno G., Isacchi G., “ Plerixafor in association with G-CSF as a mobilization regimen in patients
Date: 2014
Scope of interest: Clinical pathology
Read details
What to do to
Click on the icon of the service you are looking for and go to the dedicated section. If the service is not in the selection, go to Service Guide
